As in adult advanced phases, a recent study documented that two-thirds of pediatric patients harbor one or two BCR::ABL1 tyrosine kinase domain mutations at diagnosis (de novo CML-BP 75%, secondary CML-BP 62%) [6]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.